Montastruc J L, Chamontin B, Rascol A
Neurology. 1985 Nov;35(11):1644-7. doi: 10.1212/wnl.35.11.1644.
We studied the effects of bromocriptine therapy (mean dosage, 56.0 mg daily) for 12 months in five patients with both Parkinson's disease and hypertension. Therapy improved neurologic manifestations and reduced both supine and standing systolic blood pressures and standing diastolic blood pressure with no consistent change in heart rate. Transient episodes of orthostatic hypotension appeared in two cases. Domperidone (60 mg daily for 1 month) did not abolish the antihypertensive effect of bromocriptine, suggesting that central dopaminergic or alpha-adrenolytic mechanisms are involved in this effect. Bromocriptine may be useful in the treatment of hypertension in patients with Parkinson's disease.
我们对5例患有帕金森病和高血压的患者进行了为期12个月的溴隐亭治疗(平均剂量为每日56.0毫克)研究。治疗改善了神经学表现,降低了仰卧位和站立位收缩压以及站立位舒张压,心率无一致变化。2例出现了体位性低血压的短暂发作。多潘立酮(每日60毫克,共1个月)并未消除溴隐亭的降压作用,提示中枢多巴胺能或α-肾上腺素能机制参与了这一作用。溴隐亭可能对帕金森病患者的高血压治疗有用。